Relationship between oxidative stress markers with prostatic hyperplasia and prostate cancer

doi:10.3969/j.issn.1673-8640.2022.12.007

Abstract

Abstract:

Objective To investigate the relationship between oxidative stress markers of peripheral blood oxidative stress markers [glutathione peroxidase（GPX），superoxide dismutase（SOD），total antioxidant status（TAS），malondialdehyde（MDA） and glutathione reductase（GR）] with prostatic hyperplasia and prostate cancer. Methods A total of 222 patients with prostatic hyperplasia，136 patients with prostate cancer and 194 healthy subjects were enrolled. The levels of GPX，SOD，GR，TAS and MDA were determined. According to Gleason score，prostate cancer patients were classified into 6-7，8 and 9-10 groups. Binary Logistic regression analysis was used to evaluate the relationship between oxidative stress markers with prostatic hyperplasia and prostate cancer. Results The levels of SOD and TAS in healthy control group，prostatic hyperplasia group and prostate cancer group，were decreased successively（P<0.001），and MDA levels were increased（P<0.001）. There was no statistical significance in GPX and GR levels among the 3 groups（P>0.05）. For Gleason score 6-7，8 and 9-10 groups，SOD and TAS levels were decreased（P<0.001）. There was no statistical significance in the levels of GPX，GR and MDA among the 3 groups（P>0.05）. Binary Logistic regression analysis showed that with the healthy control group as a reference，and after adjusting for age，body mass index，smoking history，alcohol history，hypertension history and diabetes mellitus history，SOD decreasing，TAS decreasing and MDA increasing were independent risk factors for prostatic hyperplasia [odds ratios（OR）were 1.014，8.117 and 1.020] and prostate cancer （OR were 1.054，22.894 and 1.256，respectively）. With the prostatic hyperplasia group as a reference，after adjusting for age，body mass index，smoking history，alcohol history，hypertension history and diabetes mellitus history，SOD decreasing，TAS decreasing and MDA increasing were independent risk factors for prostate cancer（OR were 1.040，15.577 and 1.012，respectively）. Conclusions The decrease of SOD and TAS levels and the increase of MDA levels may be related to the occurrence of prostatic hyperplasia and prostate cancer，suggesting that oxidative stress disorder plays a role in the occurrence and development of prostatic hyperplasia and prostate cancer.

Key words: Superoxide dismutase, Total antioxidant status, Malondialdehyde, Glutathione peroxidase, Glutathione reductase, Prostatic hyperplasia, Prostate cancer

CLC Number:

Q554

WANG Linlin, XU Lili, FAN Jun, QIAN Yu. Relationship between oxidative stress markers with prostatic hyperplasia and prostate cancer[J]. Laboratory Medicine, 2022, 37(12): 1135-1140.

Figures/Tables 6

References 18

1	刘柏基, 熊波波. 慢性炎症与前列腺增生及前列腺癌发展的研究进展[J]. 世界最新医学信息文摘, 2019, 19(46):84-86.
2	PERNAR C H, EBOT E M, WILSON K M, et al. The epidemiology of prostate cancer[J]. Cold Spring Harb Perspect Med, 2018, 8(12):a030361. DOI URL
3	权衡, 朱婧, 廖焕金, 等. p2PSA、p2PSA%、PHI在前列腺癌辅助诊断中的价值[J]. 检验医学, 2021, 36(7):705-709.
4	张慧芬, 张琨, 吴书莹, 等. 氧化应激与卵巢癌发病机制相关性的研究进展[J]. 现代肿瘤医学, 2017, 25(18):3004-3008.
5	班晨, 王钟华, 安峰. SOD、TGF-β1、Vasohibin-1在口腔鳞状细胞癌诊断及预后评估中的价值[J]. 分子诊断与治疗杂志, 2021, 13(4):555-558.
6	孙昕, 王义高. 超氧化物歧化酶、丙二醛和细胞因子在肺肿瘤患者中的表达[J]. 现代肿瘤医学, 2009, 17(11):2120-2122.
7	王家芷, 王成. 血清IgA、IgG、IgM检测在前列腺炎疗效评估中的应用[J]. 检验医学, 2018, 33(12):1094-1097.
8	刘丹, 白雪, 刘桂敏, 等. 前列腺增生症发病机制的研究进展[J]. 实用临床医药杂志, 2021, 25(5):112-117.
9	卢启基, 陈征, 秦晓平, 等. 根治性前列腺切除术后Gleason评分升级的研究进展[J]. 中华泌尿外科杂志, 2020, 41(12):953-956.
10	KIM J, KIM J, BAE J S. ROS homeostasis and metabolism:a critical liaison for cancer therapy[J]. Exp Mol Med, 2016, 48(11):e269. DOI URL
11	SAURIASARI R, ANDRAJATI R, AZIZAHWATI, et al. Marker of lipid peroxidation related to diabetic nephropathy in Indonesian type 2 diabetes mellitus patients[J]. Diabetes Res Clin Pract, 2015, 108(1):193-200. DOI URL
12	王钟华, 杨永超, 安峰. SOD、DDR1、HIF-1α表达与舌鳞状细胞癌病理特征和预后的关系[J]. 分子诊断与治疗杂志, 2022, 14(5):752-755.
13	曹修娥, 栾芳, 刘义庆, 等. 卵巢癌患者SOD、Hcy和CA125的变化及与临床病理参数的相关性研究[J]. 国际检验医学杂志, 2019, 40(6):666-669.
14	YE X, WEINBERG R A. Epithelial-mesenchymal plasticity:a central regulator of cancer progression[J]. Trends Cell Biol, 2015, 25(11):675-686. DOI URL
15	CHETEH E H, AUGSTEN M, RUNDQVIST H, et al. Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death[J]. Cell Death Dis, 2017, 8(6):e2848. DOI URL
16	MIRAHMADI M, AZIMI-HASHEMI S, SABURI E, et al. Potential inhibitory effect of lycopene on prostate cancer[J]. Biomed Pharmacother, 2020, 129:110459. DOI PMID
17	ANSARI M S, GUPTA N P. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer[J]. BJU Int, 2003, 92(4):375-378. PMID
18	SCHULTZ M A, ABDEL-MAGEED A B, MONDAL D. The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells[J]. Cancers(Basel), 2010, 2(2):1354-1378.

组别	例数	年龄/岁	体质量指数/（kg/m²）	糖尿病史/例	高血压史/例	吸烟史/例	饮酒史/例
前列腺癌组	136	68.76±13.67	22.58±2.99	24	20	67	62
前列腺增生组	222	69.28±12.70	22.93±2.91	52	48	101	90
正常对照组	194	67.34±8.32	22.14±3.39	34	40	94	80
统计值		0.748	1.660	2.845	2.774	0.598	0.959
P值		0.474	0.192	0.241	0.250	0.742	0.619

组别	例数	年龄/岁	体质量指数/（kg/m²）	糖尿病史/例	高血压史/例	吸烟史/例	饮酒史/例
前列腺癌组	136	68.76±13.67	22.58±2.99	24	20	67	62
前列腺增生组	222	69.28±12.70	22.93±2.91	52	48	101	90
正常对照组	194	67.34±8.32	22.14±3.39	34	40	94	80
统计值		0.748	1.660	2.845	2.774	0.598	0.959
P值		0.474	0.192	0.241	0.250	0.742	0.619

组别	例数	GPX/（U/L）	GR/（U/L）	SOD/（U/mL）	TAS	MDA/（μmol/L）
前列腺癌组	136	56.15±12.48	62.21±13.38	131.08±24.12^*	1.06±0.09^*	20.71±6.28^*
前列腺增生组	222	55.87±11.11	60.05±12.67	163.77±31.07^*#	1.11±0.07^*#	16.80±4.78^*#
正常对照组	194	57.65±9.35	60.47±10.19	172.72±40.36	1.20±0.28	6.52±1.82
统计值		0.755	0.710	33.408	13.624	8.149
P值		0.471	0.493	<0.001	<0.001	<0.001

组别	例数	GPX/（U/L）	GR/（U/L）	SOD/（U/mL）	TAS	MDA/（μmol/L）
前列腺癌组	136	56.15±12.48	62.21±13.38	131.08±24.12^*	1.06±0.09^*	20.71±6.28^*
前列腺增生组	222	55.87±11.11	60.05±12.67	163.77±31.07^*#	1.11±0.07^*#	16.80±4.78^*#
正常对照组	194	57.65±9.35	60.47±10.19	172.72±40.36	1.20±0.28	6.52±1.82
统计值		0.755	0.710	33.408	13.624	8.149
P值		0.471	0.493	<0.001	<0.001	<0.001

组别	例数	GPX/（U/L）	GR/（U/L）	SOD/（U/mL）	TAS	MDA/（μmol/L）
6~7分组	51	55.79±8.27	61.68±8.88	143.02±18.02	1.15±0.056	17.67±13.64
8分组	41	52.82±9.65	59.14±10.22	131.05±17.40^*	1.05±0.020^*	23.64±24.81
9~10分组	44	59.15±17.06	65.19±18.43	114.71±25.75^*#	0.97±0.030^*#	26.99±25.48
F值		1.399	1.228	11.941	131.341	2.660
P值		0.254	0.333	<0.001	<0.001	0.078